Company research
ABVC BIOPHARMA, INC.
CIK 1173313Updated Sep 24, 2026
SecurityABVC · NASDAQ · equity
Name history
American BriVision (Holding) Corp · through Apr 8, 2021METU BRANDS, INC. · through Jan 8, 2016Ecology Coatings, Inc. · through Sep 2, 2015ECOLOGY COATINGS, INC. · through Sep 2, 2015OCIS CORP · through Jun 13, 2007
ABVC price & chart
Loading TradingView…
NASDAQ:ABVC on TradingView ↗About the company
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company’s network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.
In the news
No coverage from other publishers is available.
Recent filings
PRER14A filing
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Regulation FD Disclosure
Items 1.01, 2.01, 7.01, 9.01
PRER14A filing
424B4 filing
424B4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 21,062,203Source | 7,539,907Source | 14,492,599Source | 9,855,475Source |
| Property, Plant and Equipment, NetUSD | 12,835,409Source | 511,088Source | 7,969,278Source | 573,978Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 681,480Source | 248,382Source | 60,155Source | 85,265Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 1,530Source | 98,325Source |
| Assets, CurrentUSD | 2,501,343Source | 2,179,815Source | 1,656,709Source | 2,987,247Source |
| Prepaid Expense and Other Assets, CurrentUSD | 346,616Source | 96,213Source | 101,051Source | 150,235Source |
| Operating Lease, Right-of-Use AssetUSD | 1,913,278Source | 640,387Source | 809,283Source | 1,161,141Source |
| Other Assets, NoncurrentUSD | 116,966Source | 133,121Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 7,764,723Source | 6,815,948Source | 6,361,627Source | 6,619,336Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 25,053Source | 13,868Source | 7,940Source | 32,857Source |
| Additional Paid in CapitalUSD | 96,008,258Source | 78,595,065Source | 82,636,966Source | 67,907,479Source |
| Retained Earnings (Accumulated Deficit)USD | -76,858,361Source | -68,949,807Source | -65,420,095Source | -54,904,439Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 487,602Source | 445,665Source | 516,387Source | — |
| Stockholders' Equity Attributable to ParentUSD | 11,111,861Source | 1,226,140Source | 8,388,050Source | 3,098,585Source |
| Liabilities and EquityUSD | 21,062,203Source | 7,539,907Source | 14,492,599Source | 9,855,475Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 6,163,976Source | 6,557,461Source | 5,932,490Source | 5,819,529Source |
| Operating Lease, Liability, CurrentUSD | 317,557Source | 403,581Source | 401,826Source | 369,314Source |
| Operating Lease, Liability, NoncurrentUSD | 1,600,747Source | 236,807Source | 407,457Source | 791,827Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 2,185,619Source | -502,181Source | -257,078Source | 137,554Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | 3,696,380Source | 2,909,587Source |
| Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after TaxUSD | — | — | — | -517,128Source |
| Short-term InvestmentsUSD | 64,354Source | 64,736Source | 79,312Source | 75,797Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -8,376,959Source | -5,259,037Source | -10,910,288Source | -16,312,374Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 23,799Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,142,816Source | 2,773,460Source | 1,635,708Source | 7,036,778Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | -228,557Source | 614,166Source |
| Increase (Decrease) in InventoriesUSD | 11,460Source | — | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | 115,668Source | 864,802Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -2,986,299Source | -1,809,145Source | -4,235,845Source | -7,398,391Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -1,208,790Source | — | -360,186Source | -1,721,684Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 21,201Source | 119,692Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 4,637,995Source | 1,980,769Source | 3,918,960Source | 4,013,925Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 463,170Source | 147,035Source | -674,948Source | -5,173,487Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,326,985Source | 863,815Source | 716,780Source | 1,391,728Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 31,518Source | 22,539Source | 33,180Source | 285,465Source |
| Income Taxes Paid, NetUSD | 12,077Source | 25,863Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 20,264Source | -24,589Source | 2,123Source | -67,337Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,728,148Source | 451,480Source | — | 7,036,778Source |
| DepreciationUSD | 25,330Source | 32,025Source | 28,531Source | 23,799Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | -221,888Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -77,546Source | -25,135Source | 22,690Source | -259,463Source |
| Gain (Loss) on InvestmentsUSD | -192,759Source | -339,171Source | — | — |
| Goodwill, Impairment LossUSD | — | — | — | 110,125Source |
| Income (Loss) from Equity Method InvestmentsUSD | -803,008Source | — | -221,888Source | — |
| Income Tax Expense (Benefit)USD | 24,154Source | -110,539Source | 256,006Source | 797,778Source |
| InterestExpenseNonoperatingUSD | 415,890Source | 825,899Source | — | — |
| Inventory Write-downUSD | 11,460Source | — | — | — |
| Investment Income, InterestUSD | 167,103Source | 87,358Source | 185,481Source | 187,817Source |
| Net Income (Loss) Attributable to ParentUSD | -7,908,554Source | -4,902,878Source | -10,515,656Source | -16,423,239Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -468,405Source | -356,159Source | -394,632Source | 110,865Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | 5,259,037Source | — | -16,423,239Source |
| Nonoperating Income (Expense)USD | -1,201,546Source | -664,334Source | -2,437,773Source | — |
| Operating ExpensesUSD | 7,151,259Source | 5,214,068Source | 8,066,902Source | 15,797,780Source |
| Operating Lease, ExpenseUSD | 486,281Source | 514,420Source | 358,576Source | 358,576Source |
| Other Nonoperating Income (Expense)USD | -13,642Source | 134,443Source | 3,384Source | -400,184Source |
| Proceeds from Issuance of Common StockUSD | — | — | 1,050,000Source | 3,663,925Source |
| Realized Investment Gains (Losses)USD | — | — | — | -7,446Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 296,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | 509,589Source | 152,430Source | 969,783Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 2,887,358Source | 2,261,336Source | 5,368,278Source | 6,067,545Source |
| Operating Income (Loss)USD | -7,151,259Source | -4,705,242Source | -8,216,509Source | -15,114,412Source |
| Other Nonoperating Income (Expense)USD | -13,642Source | 134,443Source | 3,384Source | -400,184Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -8,352,805Source | -5,369,576Source | -10,654,282Source | -15,514,596Source |
| Income Tax Expense (Benefit)USD | 24,154Source | -110,539Source | 256,006Source | 797,778Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -468,405Source | -356,159Source | -394,632Source | 110,865Source |
| Net Income (Loss) Attributable to ParentUSD | -7,908,554Source | -4,902,878Source | -10,515,656Source | -16,423,239Source |
| Earnings Per Share, BasicUSD per share | -0.39Source | -0.42Source | -2.43Source | -0.52Source |
| Earnings Per Share, DilutedUSD per share | -0.39Source | -0.42Source | -2.43Source | -0.5Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 20,108,944Source | 11,673,980Source | 4,335,650Source | 31,664,660Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 20,108,944Source | 11,673,980Source | 4,335,650Source | 30,153,484Source |
| Interest Expense (non-operating)USD | 415,890Source | 825,899Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 24,154Source | -110,539Source | 140,338Source | 2,400Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | -221,888Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -77,546Source | -25,135Source | 22,690Source | -259,463Source |
| Gain (Loss) on InvestmentsUSD | -192,759Source | -339,171Source | — | — |
| Goodwill, Impairment LossUSD | — | — | — | 110,125Source |
| Gross ProfitUSD | — | 508,826Source | -149,607Source | 683,368Source |
| Income (Loss) from Equity Method InvestmentsUSD | -803,008Source | — | -221,888Source | — |
| Interest ExpenseUSD | — | — | 2,493,340Source | 293,968Source |
| Interest Expense, DebtUSD | 5,516Source | 646Source | 40,878Source | — |
| Investment Income, InterestUSD | 167,103Source | 87,358Source | 185,481Source | 187,817Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | 5,259,037Source | — | -16,423,239Source |
| Nonoperating Income (Expense)USD | -1,201,546Source | -664,334Source | -2,437,773Source | — |
| Operating ExpensesUSD | 7,151,259Source | 5,214,068Source | 8,066,902Source | 15,797,780Source |
| Operating Lease, ExpenseUSD | 486,281Source | 514,420Source | 358,576Source | 358,576Source |
| Other ExpensesUSD | 151,250Source | — | — | — |
| Other IncomeUSD | — | — | — | -24,149Source |
| Realized Investment Gains (Losses)USD | — | — | — | -7,446Source |
| Research and Development ExpenseUSD | 121,085Source | 179,272Source | 1,062,916Source | 2,693,457Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 296,000Source | — | — | — |
Offerings
Registration 333-250899
Registration 333-255112
Registration 333-271416
Registration 333-280411
Registration 333-276500
Filing attachments
ea027914301ex99-1.htm · 8-K · 2026-03-03
EX-99.1 2 ea027914301ex99-1.htm PRESS RELEASE Exhibit 99.1 ABVC BioPharma Reports 2025 Form 10-K Total Assets Increase 179% to $21.06 Million as Company Strengthens Asset-Backed Licensing Model Silicon Valley, CA (March 3, 2026) - ABVC BioPharma, Inc. (NASDAQ: ABVC) today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, marking a transformative year characterized by substantial balance sheet growth and strategic long-term asset positionin…
Read attachment ↗ea026348101ex99-1_abvcbio.htm · 8-K · 2025-11-03
EX-99.1 2 ea026348101ex99-1_abvcbio.htm PRESS RELEASE Exhibit 99.1 ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 Silicon Valley, CA (November 03, 2025) - ABVC BioPharma, Inc.. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced its financial results for the quarter ended September 30, 2025, and provided a…
Read attachment ↗ea025308601ex99-1_abvcbio.htm · 8-K · 2025-08-14
EX-99.1 2 ea025308601ex99-1_abvcbio.htm PRESS RELEASE Exhibit 99.1 ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025 Silicon Valley, CA (August 14, 2025) - ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, central nervous system (CNS) disorders, and oncology/hematology, today announced its financial results for the second qu…
Read attachment ↗ea024947501ex4-1_abvcbio.htm · 8-K/A · 2025-07-18
EX-4.1 2 ea024947501ex4-1_abvcbio.htm FORM OF WARRANT Exhibit 4.1 WARRANT AGREEMENT This WARRANT AGREEMENT (this “Agreement”) is entered into as of July 15, 2025 (the “Issue Date”), by and between ABVC BioPharma, Inc., a Nevada corporation (the “Company”), and Shuling Jiang (the “Holder”). This Agreement is issued pursuant to that certain Definitive Land Purchase Agreement between the Company and the Holder dated July 15, 2025 (the “Land Agreement”). 1. Grant of Warrant: The Company her…
Read attachment ↗ea024209201ex99-1_abvcbio.htm · 8-K/A · 2025-05-14
EX-99.1 2 ea024209201ex99-1_abvcbio.htm PRESS RELEASE Exhibit 99.1 ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance Silicon Valley, CA - May 14, 2025 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced that it has received official notice from the Nasdaq Listing Qualifications Department confirming that the Compan…
Read attachment ↗ea024006301ex99-1_abvcbio.htm · 8-K · 2025-05-01
EX-99.1 2 ea024006301ex99-1_abvcbio.htm PRESS RELEASE Exhibit 99.1 ABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan Silicon Valley, CA - May 01, 2025 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system, oncology, and ophthalmology indications, today announced its financial results for the first quarter ended March 31,…
Read attachment ↗